R&D Tax Credits and Selling a Business

How do R&D Credits Affect the M&A Process?

It is no small secret that the Research and Development Tax Credit is one of the most popular tax strategies for startups and small businesses. The credit offers a dollar-for-dollar offset to income taxes (or payroll taxes for qualified startups) for any company engaged in qualified research activities (QRA).

Many companies engage in R&D with an aim to eventually sell the business, thus it is important to think about how R&D Tax Credits can become a part of a business transaction.

Legal Exposure

As I mentioned, R&D Tax Credits have become extremely popular. With this increase in popularity, many companies have sought to qualify their QRA and calculate their R&D expenses without any expert guidance.

The definition of R&D under this tax credit is often more complex than people understand, and the IRS knows that this can lead to companies misstating R&D expenses or failing to provide sufficient substantiation. As a result, the IRS has sought to litigate this issue and has won victories against taxpayers that had a weak legal defense.

Due Diligence Red Flags

Large corporations have come to understand that claiming R&D credits without a backup study and legal framework presents legal risk during a transaction.

As we teach our clients through our Strategic Valuation process, a buyer's due diligence team will look for any exposure that will allow them to discount their price offering.

We have seen buyers become wary when a business is claiming significant R&D Tax Credits with no backing study. As of this writing we are working with a client who has a large buyer in the tech industry expressing concerns over the legal exposure from a lack of reporting behind their R&D Credit claim.

The Documentation Problem

When a buyer discovers that you've claimed R&D credits without proper documentation:

Price discount: Expect a 2-5% reduction in purchase price to account for potential IRS exposure
Escrow holdback: Buyers often hold back 10-15% of the purchase price in escrow for 2-3 years
Indemnification provisions: You may be personally liable for any IRS adjustments post-close
Deal termination: In extreme cases, buyers walk away entirely

This underscores the importance of making sure that proper due diligence and backup is performed when claiming R&D Tax Credits.

Real-World Example

Software company claiming $400K in annual R&D credits:

Without proper study:

Buyer offers $8M
Requests $1.5M escrow holdback
Demands 3-year indemnification period
Discounts price by $500K for perceived risk
Net proceeds at close: $6.5M

With proper study and documentation:

Buyer offers $8.5M
Standard $500K escrow
18-month indemnification period
No discount for R&D credit risk
Net proceeds at close: $8M

Difference: $1.5M - all because of documentation quality.

Improves Free Cash Flow

Utilizing R&D Tax Credits can help the seller in a transaction. Reducing either income or payroll taxes will lead to a higher free cash flow (FCF) calculation.

This can be used as tool by the seller to negotiate a higher price with the buyer since there can be an expected increase in cash flow opposed to a comparable company that does not have such tax credits.

How Buyers Value Cash Flow

The goal of the buyer is always to try to discount their estimate of a selling company's present value. Most acquisitions are valued on a multiple of:

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization)
Revenue (for high-growth companies)
Free Cash Flow (for mature businesses)

R&D tax credits improve all three metrics by reducing tax liability.

The Multiplier Effect

Here's where it gets interesting: buyers don't just pay dollar-for-dollar for tax savings. They pay a multiple.

Example:

Annual R&D tax credit: $300K
Industry valuation multiple: 6x EBITDA
Increase in enterprise value: $1.8M

Let that sink in. A $300K annual tax credit can add $1.8M to your purchase price.

Valuation Impact by Industry

Different industries apply different multiples to R&D credit savings:

Software/SaaS:

Typical multiple: 8-12x
$200K credit → $1.6M - $2.4M valuation increase

Manufacturing:

Typical multiple: 4-6x
$500K credit → $2M - $3M valuation increase

Biotech/Life Sciences:

Typical multiple: 3-5x (or based on milestones)
$400K credit → $1.2M - $2M valuation increase

Professional Services:

Typical multiple: 2-4x
$150K credit → $300K - $600K valuation increase

Deferred Tax Assets

It's not uncommon for startups and companies that spent a lot of money on R&D to carry forward unused R&D Tax Credits (credits can be carried forward for 20 years).

In these cases, unused credits become a deferred tax asset (DTA) balance sheet item.

Understanding DTAs

While it's true that DTAs are only seen as valuable if there will be future profit, most M&A transactions are done on the buyer's expectation that the selling company can be profitable.

Therefore, R&D Tax Credit DTAs can help increase a company's valuation since they provide the buyer with:

Future tax savings
Improved cash flows
Enhanced returns on investment

The DTA Discount

Buyers typically value DTAs at a discount to face value because:

Timing uncertainty: The credits might not be used immediately
Realization risk: Future profitability isn't guaranteed
Section 382 limitations: Ownership changes can limit credit usage

Typical DTA valuations:

Well-documented credits: 60-80% of face value
Poorly documented credits: 20-40% of face value
No documentation: 0-10% of face value (or ignored entirely)

Example: SaaS Company with Credit Carryforwards

Company profile:

Currently unprofitable (growing rapidly)
$2M in unused R&D credit carryforwards
Proper documentation and studies
Buyer expects profitability within 18 months

Buyer's valuation of credits:

Face value: $2M
Discount: 30% (due to timing)
Valued at: $1.4M

This $1.4M becomes part of the enterprise value calculation and increases the total purchase price.

Strategic Timing

This underscores the importance of ensuring that a company that plans to sell is taking advantage of R&D Tax Credits, even if there is no potential for immediate tax savings.

Many founders make the mistake of thinking:

"We're not profitable yet, so R&D credits don't matter"
"We'll worry about tax credits when we have a tax bill"
"It's not worth the hassle if we can't use them now"

This is shortsighted.

If you're building a company for acquisition, R&D credit DTAs are future currency. Start building them now, even if you can't use them today.

Section 382 Limitations

There's one important caveat: Section 382 limits the use of tax attributes (including R&D credits) after an ownership change.

What is Section 382?

When more than 50% of a company's ownership changes hands within a 3-year period, IRC Section 382 limits how much of the tax attributes can be used post-acquisition.

Annual limitation formula:

Long-term tax-exempt rate × Company value before acquisition
Currently around 4-5%

Real-World Impact

Example:

Company with $3M in R&D credit carryforwards
Acquired for $20M
Section 382 annual limit: $1M (5% × $20M)
Result: Credits must be used over 3+ years instead of immediately

This doesn't eliminate the value - it just defers it. Buyers factor this into their valuation models.

Planning Around 382

Smart tax planning can help:

Section 382 exception for small businesses: Certain ownership changes don't trigger 382
Increased valuation: Higher purchase price = higher annual limit
Timing of credit generation: Generate credits closer to acquisition date
Buyer's existing income: Credits can offset buyer's income in some structures

M&A Strategy: Maximizing R&D Credit Value

Obviously, R&D Credits are one of many variables in the overall due diligence process. However, as these credits become increasingly valuable, it is important to have an expert in your pocket who can help quantify and substantiate any tax credit claim.

12-24 Months Before Sale

Action items:

Conduct comprehensive R&D study: Document all qualifying activities
Calculate carryforwards: Know exactly what credits you have
Implement tracking systems: Start documenting current-year activities
Clean up historical claims: Amend if necessary to strengthen position
Consider IRS pre-approval: CAM (Compliance Assurance Process) for large credits

6-12 Months Before Sale

Action items:

Prepare due diligence package: Have all R&D documentation ready
Quantify buyer benefit: Model how credits will benefit the acquirer
Section 382 analysis: Understand limitations and plan accordingly
State credit review: Don't forget state-level credits
Legal opinion letter: Get tax counsel to bless your positions

During Due Diligence

What buyers will ask for:

R&D tax credit studies and supporting documentation
Forms 6765 from all years
Time tracking and project documentation
Technical descriptions of R&D activities
Nexus studies (for multi-state credits)
Analysis of Section 382 impact

Red flags that reduce value:

No written studies
Self-prepared calculations without technical support
Missing or incomplete Form 6765s
No contemporaneous time tracking
Inability to describe technical uncertainty

Post-Close Considerations

Even after closing, R&D credits remain important:

Escrow releases: Tied to IRS audit outcomes
Indemnification claims: Buyer may seek recovery if credits are disallowed
Carryforward tracking: Buyer needs to properly apply credits post-acquisition

The Bottom Line

Three key takeaways:

Documentation is everything: Proper R&D studies can add $500K-$2M+ to your exit value
Don't wait: Build R&D credit value now, even if you can't use it immediately
Get experts involved: This is not a DIY project when millions are at stake

Financial Impact Summary

Well-documented R&D credits:

Increase enterprise value by 4-10x annual credit amount
DTAs valued at 60-80% of face value
Minimal escrow holdbacks
Smooth due diligence process

Poorly documented or no R&D credits:

2-5% purchase price discount for perceived risk
10-15% escrow holdbacks
Extended indemnification periods
Deal delays or termination

The difference can easily be $1M-$3M on a $10M-$20M transaction.

Next Steps for Business Owners

If you're planning to sell your business in the next 1-5 years:

Audit your current R&D credit position: What have you claimed? What documentation exists?
Identify unclaimed years: Can you amend prior returns to add credits?
Implement proper documentation: Start tracking today for current-year activities
Calculate potential value: Model how credits could impact your exit value
Engage specialists: Work with R&D credit experts who understand M&A

The sooner you start, the more value you'll build.

Get Expert Help

At ATS, we specialize in helping business owners maximize R&D credit value before and during M&A transactions.

Our Strategic Valuation process includes:

Comprehensive R&D credit studies
Multi-year credit calculation and documentation
M&A-ready due diligence packages
Section 382 analysis and planning
Buyer benefit modeling
Post-transaction support

We've helped clients add $500K to $5M in transaction value through proper R&D credit documentation and strategy.

Don't leave money on the table. If you're considering a sale, contact us to discuss how R&D credits can become a powerful part of your exit strategy.

R&D Tax Credits and Selling a Business